- PR Newswire•8 hours agoAllergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
DUBLIN and BUDAPEST, Hungary, Jan. 17, 2017 /PRNewswire/ -- Allergan Plc (AGN) and Gedeon Richter Plc. today announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids. A new drug application filing for ulipristal acetate is planned for the second half of 2017. "We are pleased with the favorable results of Venus II supporting the efficacy and safety profile of ulipristal acetate as shown in our Venus I trial," said David Nicholson, Chief Research and Development Officer, Allergan.
Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.
- TheStreet.com•3 days ago
In highlights from this week's trading diary and posts, Kass tells us about how he's selling some Allergan shares and how he feels about the jobless claims.
AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||213.22 - 214.66|
|52 Week Range||184.50 - 301.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.00|
|Dividend & Yield||2.80 (1.30%)|
|1y Target Est||N/A|